Neuland Laboratories announces completion of USFDA inspection of its Unit 1 at Bonthapally, Hyderabad
Granules India announced that the USFDA has issued Establishment Inspection Report (EIR) for Company's Bonthapally facility located at Hyderabad, Telangana, India.
This facility was inspected by USFDA in July 2019 and there was one (1) observation during the inspection.
Bonthapally facility is one of the world's largest single site Paracetamol API manufacturing plant by volume. Along with Paracetamol APIs, the Company has established Metformin and Guaifenesin API manufacturing plants in the same facility.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)